What is Lamivudine With Zidovudine (Combivir)?
Lamivudine and zidovudine are in a class of drugs called reverse transcriptase inhibitors that also includes zalcitabine (Hivid) and didanosine (Videx). Lamivudine and zidovudine block the activity of reverse transcriptase and block the production of DNA and new viruses. Specifically, lamivudine is converted within the body to its active form, lamivudine triphosphate, and zidovudine is converted to its active form, zidovudine triphosphate. The active forms are similar to the naturally occurring deoxycytidine triphosphate and thymidine triphosphate, respectively, chemicals that are used by reverse transcriptase to make DNA. The reverse transcriptase uses lamivudine triphosphate and zidovudine triphosphate instead of the naturally-occurring deoxycytidine triphosphate and thymidine triphosphate for making DNA, and these active forms of the drugs interfere with the activity of reverse transcriptase.
This drug is commonly sold as Brand Name Combivir.
Indication/Contraindication for use of Lamivudine With Zidovudine (Combivir)
Treatment of HIV infection.
Dosage and Prescribing Information for Lamivudine With Zidovudine (Combivir)
Adults and adolescents (at least 12 years of age) is one tablet (containing 150mg of lamivudine and 300mg of zidovudine) twice daily. It should not be prescribed for patients requiring dosage adjustment such as those with reduced renal function (creatinine clearance < 50 mL/min), those with low body weight (< 50 kg or 110 lb), or those experiencing dose limiting adverse events.